Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?
- PMID: 15673596
- DOI: 10.1124/dmd.104.003236
Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?
Abstract
Individual variability in cytochrome P450 (P450) induction comprises an important component contributing to the difficulties in assessing and predicting metabolism-based drug-drug interactions in humans. In this article, we outline the major factors responsible for the individual variability in P450 induction, including variable transporter activity and metabolism of inducers in vivo, genetic variations of P450 genes and their regulatory regions, genetic variations of receptors and regulatory proteins required for induction, and different physiological and environmental elements. With a better understanding of the major determinants in P450 induction and a profile of the phenotypes of these determinants in each individual, it is believed that the individual variability in induction-mediated drug-drug interactions can be adequately evaluated.
Similar articles
-
Characterization of human cytochrome P450 enzymes.FASEB J. 1992 Jan 6;6(2):745-8. doi: 10.1096/fasebj.6.2.1537465. FASEB J. 1992. PMID: 1537465 Review.
-
The human drug metabolizing cytochromes P450.J Pharmacokinet Biopharm. 1996 Oct;24(5):461-73. doi: 10.1007/BF02353474. J Pharmacokinet Biopharm. 1996. PMID: 9131485 Review.
-
Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.J Pharmacokinet Biopharm. 1996 Oct;24(5):475-90. doi: 10.1007/BF02353475. J Pharmacokinet Biopharm. 1996. PMID: 9131486 Review.
-
Drugs as CYP3A probes, inducers, and inhibitors.Drug Metab Rev. 2007;39(4):699-721. doi: 10.1080/03602530701690374. Drug Metab Rev. 2007. PMID: 18058330 Review.
-
Failure in drug development: the role of inhibition and induction of cytochrome P450 enzymes.Arch Toxicol. 2008 Oct;82(10):665-6. doi: 10.1007/s00204-008-0355-1. Arch Toxicol. 2008. PMID: 18751968 No abstract available.
Cited by
-
Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.Viruses. 2021 Dec 31;14(1):69. doi: 10.3390/v14010069. Viruses. 2021. PMID: 35062273 Free PMC article.
-
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.Antimicrob Agents Chemother. 2011 Dec;55(12):5616-23. doi: 10.1128/AAC.05265-11. Epub 2011 Sep 26. Antimicrob Agents Chemother. 2011. PMID: 21947399 Free PMC article. Clinical Trial.
-
Pharmacokinetic drug interactions in liver disease: An update.World J Gastroenterol. 2016 Jan 21;22(3):1260-78. doi: 10.3748/wjg.v22.i3.1260. World J Gastroenterol. 2016. PMID: 26811663 Free PMC article. Review.
-
Transfer learning enhanced graph neural network for aldehyde oxidase metabolism prediction and its experimental application.Acta Pharm Sin B. 2024 Feb;14(2):623-634. doi: 10.1016/j.apsb.2023.10.008. Epub 2023 Oct 20. Acta Pharm Sin B. 2024. PMID: 38322350 Free PMC article.
-
The Genetic Background of Endometriosis: Can ESR2 and CYP19A1 Genes Be a Potential Risk Factor for Its Development?Int J Mol Sci. 2020 Nov 3;21(21):8235. doi: 10.3390/ijms21218235. Int J Mol Sci. 2020. PMID: 33153202 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical